Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Inclusion Criteria:

Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment
Total WBC recovery of 500 mm3 prior to IL-2 treatment
Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment
Active infection controlled prior to starting IL-2 treatment
Stable systolic blood pressure > 90mm Hg prior to starting IL-2 treatment
O2 saturation >90% prior to starting treatment
Stable cardiopulmonary status prior to starting IL-2 treatment
Serum creatinine < or equal to 2.0 mg/dl
Total bilirubin and AST <3x upper limits normal

Exclusion Criteria:

Acute Promyelocytic Leukemia
Active thrombocytopenic bleeding
Cardiac ejection fraction below 45%
Pregnancy and/or lactation